Spyre Therapeutics launches underwritten public offering of common stock

• Spyre Therapeutics launched an underwritten public offering of common stock.
• Underwriters receive a 30-day option to buy up to 15% additional shares on the same terms.
• Jefferies, TD Cowen, Leerink Partners, Stifel serve as joint bookrunners; LifeSci Capital acts as passive bookrunner.
• Proceeds earmarked for immunology pipeline development, including SPY072 late-stage work in hidradenitis suppurativa.
• Deal terms remain subject to market conditions; pricing, size, timing not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051601PRIMZONEFULLFEED9839893) on October 05, 2026, and is solely responsible for the information contained therein.